Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.60 |
| ▸ | HTR1A | P08908 | 3/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.60 |
| ▸ | DRD1 | P21728 | 3/20 | 0.60 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.60 |
| ▸ | DRD3 | P35462 | 3/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.60 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.60 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxomemazine SCHEMBL29378205 | 1.00 | LMNA (0.60) | LMNACHRM2HTR1AADRA2ACHRM1 | |
| Oxomemazine SCHEMBL4420096 | 0.98 | LMNA (0.58) | LMNACHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL22882778 | 0.78 | CHRM2 (0.55) | LMNACHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL7344181 | 0.78 | RXFP1 (0.42) | LMNACHRM2HTR1AADRA2ACHRM1 | |
| Oxomemazine SCHEMBL28086314 | 0.76 | CYP2D6 (0.60) | LMNACHRM2HTR1AADRA2ACHRM1 | |
| Trimipramine SCHEMBL117756 | 0.75 | SLC6A4 (1.00) | LMNACHRM2HTR1AADRA2ACHRM1 | |
| Trimipramine SCHEMBL5494378 | 0.75 | SLC6A4 (1.00) | LMNACHRM2HTR1AADRA2ACHRM1 | |
| Methylpromazine SCHEMBL18993 | 0.75 | CHRM2 (1.00) | LMNACHRM2HTR1AADRA2ACHRM1 | |
| Trimipramine SCHEMBL35144 | 0.75 | SLC6A4 (1.00) | LMNACHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL12265313 | 0.75 | CYP2D6 (0.63) | LMNACHRM2HTR1AADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 604 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-4691492-A2 | LIQUID COMPOSITIONS | Kenvue Brands LLC (US) | 2026-02-11 | — | — | EP | claimed |
| WO-2025082959-A1 | A PHENOTHIAZINE-RELATED COMPOUND CONJUGATED TO A PEPTIDE | UNIVERSITY OF ULSTER (GB) | 2025-04-24 | — | — | WO | claimed |
| US-20250041208-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2025-02-06 | — | — | US | claimed |
| EP-4444277-A1 | NEW INJECTABLE COMBINATION FORMULATION | Nanexa AB (SE) | 2024-10-16 | — | — | EP | claimed |
| WO-2023105227-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2023-06-15 | — | — | WO | claimed |
| US-20230181556-A1 | USE OF PSYCHOTROPIC DRUGS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP) (FR) | 2023-06-15 | — | — | US | claimed |
| EP-4153158-A1 | USE OF PSYCHOTROPIC DRUGS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2023-03-29 | — | — | EP | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| WO-2021233899-A1 | USE OF PSYCHOTROPIC DRUGS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-11-25 | — | — | WO | claimed |
| EP-1919450-A1 | ANTIHISTAMINE- AND CORTICOSTEROID- CONTAINING LIPOSOME COMPOSITION AND ITS USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING RHINITIS AND RELATED DISORDERS | Biolipox AB (SE) | 2008-05-14 | — | — | EP | claimed |
| EP-1888033-A2 | METHOD AND COMPOSITION FOR TREATING INFLAMMATORY DISORDERS | Biolipox AB (SE) | 2008-02-20 | — | — | EP | claimed |
| EP-1832287-A2 | The use of anti-histaminics for acute reduction of elevated intracranial pressure | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-12 | — | — | EP | claimed |
| WO-2007036671-A2 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL GALENIC FORM COMPRISING SAME | FLAMEL TECHNOLOGIES (FR) | 2007-04-05 | — | — | WO | claimed |
| WO-2007026151-A1 | ANTIHISTAMINE- AND CORTICOSTEROID- CONTAINING LIPOSOME COMPOSITION AND ITS USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING RHINITIS AND RELATED DISORDERS | BIOLIPOX AB (SE) | 2007-03-08 | — | — | WO | claimed |
| WO-2006131737-A2 | METHOD AND COMPOSITION FOR TREATING INFLAMMATORY DISORDERS | BIOLIPOX AB (SE) | 2006-12-14 | — | — | WO | claimed |
| EP-1641446-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | Pediamed Pharmaceuticals, Inc. (US) | 2006-04-05 | — | — | EP | claimed |
| WO-2004112771-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | PEDIAMED PHARMACEUTICALS, INC. (US) | 2004-12-29 | — | — | WO | claimed |
| US-20040259809-A1 | Pharmaceutical compositions including an antihistamine and a stimulant and method of use thereof | PEDIAMED PHARMACEUTICALS, INC. | 2004-12-23 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |